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Abstract
Although the efficacy of methadone maintenance treatment (MMT) in opioid dependence disorder has been well
established, the influence of methadone pharmacokinetics in dose requirement and clinical outcome remains controversial.
The aim of this study is to analyze methadone dosage in responder and nonresponder patients considering
pharmacogenetic and pharmacokinetic factors that may contribute to dosage adequacy. Opioid dependence patients
(meeting Diagnostic and Statistical Manual of Mental Disorders, [4th Edition] criteria) from a MMT community program were
recruited. Patients were clinically assessed and blood samples were obtained to determine plasma concentrations of (R,S)-,
(R) and (S)- methadone and to study allelic variants of genes encoding CYP3A5, CYP2D6, CYP2B6, CYP2C9, CYP2C19, and P-
glycoprotein. Responders and nonresponders were defined by illicit opioid consumption detected in random urinalysis. The
final sample consisted in 105 opioid dependent patients of Caucasian origin. Responder patients received higher doses of
methadone and have been included into treatment for a longer period. No differences were found in terms of genotype
frequencies between groups. Only CYP2D6 metabolizing phenotype differences were found in outcome status, methadone
dose requirements, and plasma concentrations, being higher in the ultrarapid metabolizers. No other differences were
found between phenotype and responder status, methadone dose requirements, neither in methadone plasma
concentrations. Pharmacokinetic factors could explain some but not all differences in MMT outcome and methadone
dose requirements.
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Introduction
Maintenance treatment of opioid dependence with methadone
is a well known pharmacotherapy approach. However, there is a
large interindividual variability in clinical outcomes among
subjects in methadone maintenance treatment (MMT) [1]. In
fact, between the 30% and 80% of patients receiving methadone
are poor responders when retention in the MMT and/or illicit
opioid use are considered as the main outcome variables [2,3].
Several factors like, poor coping self-efficacy [4], mood states [5],
genetic polymorphisms in drug metabolizing enzymes [6], and
methadone pharmacokinetics [5] have been suggested as contrib-
uting factors. One of the main factors related to MMT success is
the dose of methadone provided [7–9].
Although a strong correlation between methadone dose and
concentrations in plasma has been reported [10], this relationship
may not be linear, and it has been shown that the determination of
methadone plasma concentrations and their enantiomers is not
useful to predict illicit opioid use, nor opioid withdrawal symptoms
[11,12]. Although methadone is usually administered as a
racemate (a 50:50 mixture of two enantiomers, (R)- and (S)-
methadone), the (R)-enantiomer accounts for the majority of
opioid agonist effects [13]. The metabolic disposition of metha-
done also displays a certain degree of enantioselectivity.
Methadone is metabolized by the cytochrome P450 system
being major contributing isoenzymes CYP3A4, CYP2B6 and to a
lesser extent CYP2D6 [14]. Other isoenzymes, such as CYP1A2,
CYP2C8, CYP2C9 and CYP2C19 could also be involved in
methadone metabolism but there are contradictory data [15]. The
involvement of different isoenzymes of cytochrome P450 in
methadone metabolism should be considered to understand the
clinical pharmacology of this substance.
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CYP3A4 is the major isoenzyme of cytochrome P450 involved
in EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) for-
mation from methadone [16,17] in a non-enantioselective manner
[16,18,19]. Induction of CYP3A4 at the beginning of MMT
probably explains, at least in part, the increased EDDP/
methadone ratio [20] and justifies the need of dosage adaptation.
The activity of this enzyme is highly variable among individuals,
and can be affected by environmental and genetic factors. The
most studied allelic variant is the CYP3A4*1B allele, which was
associated with a 1.5-fold increase in transcription in vitro. In an in
vivo study by Crettol et al. [14] the carriers of the CYP3A4*1B
variant presented a 1.4-fold increase for (S)-methadone and 1.1-
fold increase for (R)-methadone; also, the CYP3A4*1B variant
carriers have more probability to be in the low-dose group,
suggesting that they have higher methadone plasma concentra-
tions and require lower methadone doses.
The hepatic expression of CYP3A5 is bimodally distributed,
indicating the existence of genetic polymorphisms [21]. Several
genetic variants have been described for CYP3A5, and the most
common, the CYP3A5*3 allele, causes the loss of CYP3A5
activity. Thus, only individuals carrying at least one CYP3A5*1
allele express large amounts of CYP3A5 [22,23]. This polymor-
phism has been reported to influence total CYP3A activity and
shows ethnic differences in its frequency [24]. Thus, a substantial
change in CYP3A5 activity might influence the pharmacokinetics
of CYP3A substrates [25]. In fact, it has been shown that patients
with CYP3A5*1/*1 and *1/*3 genotypes require a significantly
higher sirolimus daily dose to achieve the same blood concentra-
tion at steady-state as *3/*3 patients [26]. Furthermore, in most
cases, subjects expressing CYP3A5 also express very high levels of
CYP3A4. Therefore, even if CYP3A5 was not shown to play an
active role in methadone metabolism in vitro [27,28] since it may
represent up to 50% of the total hepatic CYP3A content in
subjects expressing it [23], and in view of the fact that subjects
expressing it also have very high levels of CYP3A4 activity, it
might be an important contributor to the interindividual
variability in methadone metabolism.
CYP2D6
CYP2D6 is expressed in the liver and is subject to genetic
polymorphism. In vitro studies show a minor role of CYP2D6 in
the formation of EDDP from methadone [16] with a enantiose-
lectivity towards (R)-methadone [29]. However, observed phar-
macokinetic interactions between methadone and CYP2D6
inhibitors seem to indicate a more relevant contribution to
methadone metabolic disposition [30,31]. CYP2D6 displays a
genetic polymorphism with as many as one hundred allelic
variants. Among them, variants *3 to *8 are nonfunctional, *9,
*10, *41 have reduced functionality, and *1, *2, *35, *4 and *41
can be duplicated, resulting in an increased expression of
functional (or non-functional) CYP2D6 protein. Allele combina-
tions determine CYP2D6 phenotype, which includes the poor
metabolizer (PM; two non functional alleles), the extensive
metabolizer (EM; at least one functional allele), the intermediate
metabolizers (IM; two decreased activity alleles) and the ultra-
rapid metabolizer (UM; multiple copies of a functional allele and/
or allele with promoter mutation). These phenotypes have been
related with methadone plasma concentrations [32,33]. Clinical
studies showed an influence of CYP2D6 phenotype in lower
trough (R,S)-methadone plasma concentrations [14] and in the
reported satisfaction with methadone treatment [6]. Discrepancies
between genotype and in vivo CYP2D6 activity in MMT patients
have been described [34]; the authors postulated that the finding
was consistent with inhibition of CYP2D6 activity by methadone
[35].
CYP2B6
CYP2B6 shows a cross-regulation with CYP3A4, UGT1A1 and
several hepatic drug transporters by the nuclear receptors
pregnane X receptor (PXR) and constitutive androstane receptor
(CAR). This is of relevance since CYP3A4 and drug transporters
are involved in methadone metabolic disposition [36].
In vitro and in vivo studies have shown that CYP2B6 is a
contributor to methadone metabolism [15] with an observed
enantioselectivity towards de (S)-enantiomer [18,19,37]. In vivo
studies also demonstrated that CYP2B6 genotype influences
methadone plasma concentrations, mainly (S)-methadone. Mul-
tiple SNPs within the CYP2B6 gene, located on chromosome
19q13.2, have been described [14,38]. The CYP2B6 genotype
*6/*6 is associated with a decreased activity of the protein in vitro
[36] and in previous studies of patients in methadone treatment
has been related with high (S)-methadone plasma concentrations,
with no significant effects in (R)-methadone plasma concentra-
tions [14,37]. Genotype differences were not associated with
MMT response, nor methadone dose requirements. The
stereoselectivity towards the non active enantiomer could explain
these results [14].
Other cytochromes
Available in vivo and in vitro data suggest that CYP1A2 is not
involved in methadone metabolism [15]. Other enzymes have
been recently evaluated in relationship with methadone metabo-
lism: CYP2C19 and CYP2C9. Whereas some authors describe an
influence in methadone metabolic disposition [18,39], other
authors haven’t found an influence on enantiomer methadone
plasma concentrations [14,37].
P-glycoprotein
Methadone is a substrate of P-glycoprotein (P-gp) which shows a
weak stereoselectivity towards the (S)-enantiomer [40]. It is a
trans-membrane protein of 1280 amino acids. It is expressed in
tissues with a barrier function [41]. The activity of P-gp in
intestines and the brain blood barrier has been shown to be of
some relevance in determining methadone concentrations [15]. P-
gp is encoded by the multidrug resistance 1 (ABCB1) gene on
chromosome 7p21. This gene is highly polymorphic and a number
of variants have been associated with drug response [42]. The
majority of studies focused on a non-synonymous SNP in exon 26,
3435C.T; the homozygosity to the allele T showed lower in vivo
duodenal P-gp expression [42]; also, the ABCB1 3435T allele may
alter the stability of ABCB1 mRNA and is associated with lower
mRNA concentrations [43,44].
Genetic variability of ABCB1 and effects on MMT have already
been studied. One study [45] with 60 opioid dependent subjects
in MMT showed that ABCB1 genetic variability influenced
daily methadone requirements. Other authors [14,46] showed
an influence in (R,S)-methadone plasma concentrations, but they
didn’t found any influence in therapeutic response.
Several studies have been conducted to assess the influence of
haplotypes on the clinical response to methadone, with contra-
dictory findings, probably related to methodological differences
(methadone formulations, treatment duration and previous
exposure to methadone) [15].
The study of patients’ genetic polymorphisms in genes encoding
for methadone-metabolizing enzymes and transporters has been
an active area of research but the clinical relevance in MMT
outcome is still unclear [15,47]. A cross-sectional study was
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designed to assess the influence of ABCB1 and cytochrome P450
genetic variability on methadone pharmacokinetics, dose require-
ments, and clinical response in opioid dependent patients included
in a MMT program.
Methods
Ethics Statement
Written informed consent was obtained from each subject after
they had received a complete description of the study and been
given the chance to discuss any questions or issues. The study was
approved by the Ethical and Clinical Research Committee of our
institution (CEIC-IMAS).
Design and Patients
The study recruited opioid dependence patients who met
criteria for opioid dependence following the Diagnostic and
Statistical Manual of Mental Disorders (4th Edition) [DSM-IV]
from a MMT program (MMT community program, CAS
Barceloneta, Barcelona, Spain). The main characteristics of the
MMT provided included: clinical management with individual
counseling to encourage drug abstinence, methadone dosages as
required (no restrictions for upper limit) and no restriction on
treatment duration. Forced discharge occurred only as a result of
patients’ violent behavior or drug trafficking.
To be eligible for the study, patients had to be Caucasian,
enrolled in MMT for at least four months, and receiving a stable
methadone dose for the last two months. Exclusion criteria were as
follows: language-related barriers, severe cognitive impairment,
and any medical condition that would interfere with research
assessments and refusal to take part in the study.
Clinical Assessment
A close-ended questionnaire was used to record patients’ socio-
demographic characteristics, serological status (Human Immuno-
deficiency Virus [HIV], Hepatitis C Virus [HCV]), history of
substance use, and previous psychiatric pharmacological treatment
as well as other concomitant treatments. Substance use disorders
and other psychiatric disorders were diagnosed according to
DSM-IV criteria, using the Spanish version of the Psychiatric
Research Interview for Substance and Mental Disorders (PRISM-
IV) for axis I and II (borderline and antisocial personality
disorders) [48,49]. The degree of addiction-related impairment
was assessed using the Spanish version of the Addiction Severity
Index (ASI) [50,51].
The use of illegal opiates was evaluated retrospectively by
reviewing the results of the last 4 urine tests performed over 2
months before study inclusion. Urinalyses for the detection of
heroin consumption were carried out at the centre, 1 day at
random every 1 or 2 weeks, under supervision of the nursing staff.
It was considered that illegal opiates had been used when 2 or
more urinalyses tested positive for morphine metabolites (in the
last 4 drug tests in urine). Determination of morphine and codeine
metabolites in urine was performed by a gas chromatography—
mass spectrometry method [52]. This method allows the
identification of 6-monoacetylmorphine in urine, which can be
used as a confirmatory marker of heroine abuse. These results
were used to group patients as responders (all drug tests were
negative) and nonresponders (2 or more positive drug tests).
Because the definition of the Responder and Nonresponder
phenotype is difficult to establish, it was decided to exclude
subjects with subthreshold urine controls, that is, only one positive
urine test in the last four screening procedures.
Plasma Samples Analysis
A blood sample (5 mL) was taken 24 hours after the last
supervised methadone oral administration. Due to the differences
in the opioid effect and metabolism between methadone
enantiomers, we decided to analyze plasma concentrations for
both enantiomers separately and for total methadone plasma
concentrations. The (R)-, (S)- and (R,S)- methadone plasma
concentrations were determined by capillary electrophoresis
technique (CE-UV) after a liquid-liquid extraction of samples
with tert-butylmethylether. A capillary electrophoretic system (CE,
3DHewlett-Packard) equipped with a diode-array detector (UV)
was used for the enantioselective determination of methadone. (S)-
dextrorphan and (R)-levorphanol were used as internal standards
(I.S.) for (S)- and (R)-methadone, respectively. After a liquid-liquid
extraction of 1 mL of plasma with tert-butylmethylether [12],
resolution of the enantiomers was performed in an untreated
fused-silica capillary of 48.5-cm total length (40-cm effective
length) and a standard 50-mm optical path length cell. A constant
voltage of 25 kV was applied and the cartridge temperature was
maintained at 16uC, The diode-array detector was set to monitor
the signal at 204 nm. Resolution was performed by using 1 mM
heptakis-(2,6-di-O-methyl)-b-cyclodextrin in 100 mM H3PO4,
pH = 2.5 as a running buffer [53].
Calibration curves were prepared for each analytical batch with
appropriate volumes of the corresponding racemic mixture
working solutions added to test tubes containing 1 mL of drug-
free plasma, and were linear over 100–500 ng/mL concentration
range of the corresponding enantiomers. Control plasma samples
containing 150 (low control) and 350 ng/mL (high control) of
methadone enantiomers were prepared in drug-free plasma and
were kept frozen at 220uC in 1 mL aliquots until their use.
Peak-area ratios between compounds and I.S. were used for
calculations. A weighted (1/concentration) least-square regression
analysis was used (SPSS for Windows, version 14.0). Extraction
efficiencies for (R)-methadone and (S)-methadone were calculated
by comparing the peak areas of equal concentrations of drug
extracted and non-extracted, being 99.8 and 86.7%, respectively.
Four replicate analyses were performed with plasma samples
corresponding to the first level of concentrations of the calibration
curves, and 3 and 10 standard deviations (SD) of the calculated
concentrations at this calibration level were used for estimating the
limits of detection (LOD) and quantification (LOQ), respectively,
being LOD 25.9 and 23.2 ng/mL and LOQ 78.5 and 70.2 ng/
mL for (R) and (S)-enantiomer, respectively. Precision was
calculated as the relative standard deviation (RSD) of the quality
control samples concentrations and there were 8.9% and 10.2%
for (R)- and (S)-methadone, respectively. Accuracy is expressed as
the relative error of the calculated concentrations, being 8.2 and
10.9% for (R) and (S)-methadone, respectively.
Genetic Analysis
A collection of 20 mL of blood was done to extract DNA from
leukocytes to evaluate allelic variants of genes encoding the
following proteins: cytochrome P450 3A5 (CYP3A5); cytochrome
P450 2D6 (CYP2D6); cytochrome P450 2B6 (CYP2B6), cyto-
chrome P450 CYP2C9 (CYP2C9), cytochrome P450 CYP2C19
(CYP2C19), and the Multidrug Resistance 1 transporter (ABCB1)
[42]. The genotyping of all mentioned genes but CYP2B6 was
performed using a DNA microarray (Progenika Biopharma,
Derio, Spain). Details on the allelic variants monitored per gene
as well as performance of the microarray have been previously
described [54]. Briefly, target DNA for hybridization was prepared
by amplification of all genes except CYP2D6 in several multiplex
PCR reactions. The gene CYP2D6 was amplified together with a
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shorter deletion-specific fragment in a long-range PCR reaction.
Similarly, a separate long-range multiplex PCR reaction with the
CYP2D6 gene and a short duplication-specific fragment was
carried out for the identification of individuals carrying multiple
copies of the CYP2D6 gene.
CYP2B6 genotyping of two SNP positions was performed by
TaqMan 59-nuclease chain reaction assay using commercially
available kit for 516GRT (TaqMan Drug Metabolism Genotyp-
ing Assay, Applied Biosystems, Foster City, CA) and previously
published probes (MGB TaqMan ProbesH, Applied Biosystems)
and primers for 785ARG [55]. The PCR reaction was performed
according to the manufacturer instructions on ABI PRISM 7900
sequence detection system (Applied Biosystems). The genotype for
CYP2B6 was defined by haplotype combining both tested SNPs
according to the earlier published determination [56]. Hence,
homozygous genotypes *1/*1, *4/*4 and *6/*6 correspond to the
haplotypes defined by combination of 516GG with 785AA,
516GG with 785GG, and 516TT with 785GG, respectively.
Correspondingly, the combination of SNPs for heterozygous
genotypes were 516GG with 785AG for *1/*4 and 516GT with
785 GG for *4/*6. For combination of 516GT with 785AG
detected in 51 participant of this study, there were two possible
genotypes, *1/*6 and *4/*9. Alleles *9 and *4 have of very low
frequency among Spaniards (#1.4% and#6.2% respectively) [57]
and all carriers of these combined alleles were assigned as *1/*6
heterozygous.
The genotype distribution and corresponding allelic variants
frequency were calculated.
Statistical Analysis
Descriptive statistics of all variables of interest are presented as
means and standard deviation (SD) in case of quantitative
variables, and by absolute and relative frequencies in case of
categorical variables. Differences in sociodemographic and clinical
characteristics between groups were examined using Chi-square,
One-Way ANOVA and T student (when appropriate) tests.
Differences in genotype and phenotype frequencies among
responders and nonresponders were assessed by Chi-square test.
The phenotypes were compared with respect to methadone dose
and plasma concentrations using one-way ANOVA together with
Tukey post hoc analysis for pairwise comparisons. All analyses
were performed with the statistical software package SPSS (SPSS
Inc., Chicago, IL), version 14.0.
Results
Clinical Characteristics of Patients
From 169 eligible patients, 12 were non Caucasian and were
excluded. Reliable information on patients’ medical history and on
the use of concurrent medication was obtained from 105 patients
(71% male; mean age 38 years [SD = 8]) by personal interview and
by review of the clinical records. The characteristics of patients
(already split in responders and nonresponders) are represented in
Table 1. The mean methadone dose of patients included in the
study was 98 mg/day (SD = 64). All but 2 patients were smokers
and 65% were taking concomitant treatments. Responders and
nonresponders showed similar characteristics except of, days of
heroin use in the last 30 day (responders 0 days [SD = 1] vs.
nonresponders 16 days [SD = 10]), methadone dosage (responders
109 mg/day [SD = 68] vs. nonresponders 72 mg/day [SD = 43],
p = 0.007); The lower dose of nonresponder patients cannot be
explained by restrictions for upper limit in methadone dosage in
the framework of the MMT. Also, patients groups showed
differences in terms of months in methadone (Responders 52
Table 1. Main sociodemographical and clinical characteristics
of responder and nonresponder patients groups.
Responders Nonresponders Pa
N=76 N=29
Male (%) 53 (70) 21 (72) 1.000
Age, mean 6 SD 3967 3669 0.076
Years at school 6 SD 963 863 0.060
Single (%) 30 (41) 13 (45) 0.629
Criminal background (%) 40 (54) 18 (62) 0.248
Live with family (%) 58 (78) 19 (66) 0.764
Employed (%) 22 (30) 10 (42) 0.205
HIV+(%) 31 (41) 9 (31) 0.380
HCV+(%) 59 (78) 18 (62) 0.139
Lifetime psychiatric
comorbidity (%)
45 (74) 14 (48) 0.416
Months of heroin
use 6 SD
144680 121667 0.192
Days of heroin 30
days 6 SD
061 16610 ,0.001
Days of cocaine 30
days 6 SD
266 7612 0.123
Nicotine cigarettes/
day 6 SD
22611 26613 0.172
Concomitant medication (%)
benzodiazepines 39 (51) 9 (31) 0.080
antiretrovirals 13 (17) 5 (17) 1.000
anticonvulsants 9 (12) 0 (0) 0.060
SSRI 13 (17) 1 (3) 0.106
other antidepressant
(non-SSRI)
9 (12) 4 (14) 0.750
antipsychotics 14 (18) 3 (10) 0.388
antibiotics 6 (8) 1 (3) 0.670
any concomitant medication 53 (70) 15 (52) 0.110
Months in methadone 6 SD 52649 21632 0.001
Methadone dosage
(mg/day) 6 SD
109668 72643 0.007
Methadone plasma
concentrations (ng/ml) 6 SDb
Total (R,S)-methadone 5876501 4436246 0.121
(R)-methadone 3116259 2386131 0.136
(S)-methadone 2766288 2056121 0.370
ASI scores 6 SD
General Health 362 462 0.184
Work 463 363 0.670
Alcohol Use 162 161 0.127
Drug Use 462 662 0.001
Legal 162 363 0.001
Social 363 362 0.789
Psychological 363 363 0.855
aBold numbers indicate statistically significant differences between patients.
bPlasma concentrations of methadone were obtained from 79 subjects (65
responders and 14 non-responders).
SD = standard deviation; HIV = human immundeficiency virus; HCV = hepatitis C
virus; SSRI = Selective Serotonin Reuptake Inhibitors; ASI = Addiction Serverity
Index.
doi:10.1371/journal.pone.0019527.t001
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months [SD = 49] vs. nonresponders 21 months [SD = 32],
p = 0.001), and in the Drug Use ASI scale and Legal Problems
ASI scale.
Plasma samples were obtained from 79 patients. There were no
differences between these 79 patients from which we obtained
plasma and the rest (n = 26, 11 responders and 14 nonresponders)
of patients included in the study samples in terms of socio-
demographic, neither medical nor psychopathological character-
istics. Blood samples for genotyping were usually obtained at the
inclusion of patients in the MMT. Blood samples for methadone
determination were obtained once the patient was enrolled for 4
months at the MMT and dose was stabilized (according to
inclusion criteria) in the MMT for 2 months. The main reason for
not obtaining blood samples from all patients once dose was
stabilized is the lack of cooperation for sample withdrawal.
Although it did not reach statistical significance, Responder
patients presented higher methadone plasma concentrations of
both, (R)- (responders 311 ng/ml [SD = 259] vs. nonresponders
238 ng/ml [SD = 131], p = 0.136) and (S)-methadone (responders
276 ng/ml [SD = 268] vs. nonresponders 205 ng/ml [SD = 121],
p = 0.370) and, also, (R,S)-methadone (responders 587 ng/ml
[SD = 501] vs. nonresponders 443 ng/ml [SD = 246], p = 0.121).
Globally this trend reflects differences of about 25% of methadone
dose between responder and nonresponder patients.
Genotypes and Phenotypes
The frequencies of genotypes and allelic variants screened for
are represented in Table 2 and those of the different phenotypes
are represented in Table 3. No differences were observed in the
distribution of genotypes and phenotypes for genes evaluated
among responders and nonresponders patients except for an
overrepresentation of UM subjects of CYP2D6 in responder
patients. (7% in responders versus 0% in nonresponder patients;
p = 0.032). When the (R,S)-methadone plasma concentrations
were divided by the daily methadone dose provided, no differences
were found in terms of genotypes nor phenotypes. Regarding to
CYP2B6*6, in our sample, 5 patients were *6 homozygous
carriers; 4 of them correspond to responder patients, and only one
was classified as nonresponder.
Methadone Dose Requirements, Plasma Concentrations,
and Phenotype
We studied the mean methadone dose, (R)-, (S)- and (R,S)-
methadone plasma concentrations by phenotype for all genes
evaluated. Results for all genes studied can be found in
Supplementary materials (Table S1). Results were essentially
negative except for CYP2D6 (see Table 4). We found significant
Table 2. Genotype frequencies of CYP3A5, CYP2D6, CYP2B6,
CYP2C9, CYP2C19 and ABCB1 between responder and
nonresponder groups.
Responders Nonresponders P
N=76 (%)a N=29 (%)a
CYP3A5 Genotype 0.446
*1/*1 1 (1) 1 (3)
*1/*3 11 (15) 2 (7)
*3/*3 64 (84) 26 (90)
CYP2D6 Genotype 0.211
*1/*1 4 (5) 2 (7)
*1/*2 12 (16) 4 (14)
*1/*3 2 (3) 0 (-)
*1/*4 16 (21) 3 (10)
*1/*5 1 (1) 0 (-)
*1/*6 1 (1) 0 (-)
*1/*9 2 (3) 0 (-)
*1/*10 2 (3) 0 (-)
*1/*41 1 (1) 3 (10)
*2/*2 6 (8) 2 (7)
*2/*3 1 (1) 0 (-)
*2/*4 9 (12) 6 (21)
*2/*5 1 (1) 1 (3)
*2/*6 1 (1) 1 (3)
*2/*9 2 (3) 0 (-)
*2/*35 1 (1) 0 (-)
*2/*41 1 (1) 3 (10)
*3/*17 1 (1) 0 (-)
*4/*4 2 (3) 3 (10)
*5/*41 2 (3) 0 (-)
*10/*41 1 (1) 0 (-)
*35/*35 1 (1) 0 (-)
*35/*41 0 (-) 1 (3)
*1/*263b 3 (4) 0 (-)
*2/*263b 2 (3) 0 (-)
CYP2B6 Genotypec 0.751
*1/*1 43 (57) 18 (62)
*1/*4 4 (5) 0 (-)
*1/*6 23 (30) 9 (31)
*4/*6 1 (1) 0 (-)
*6/*6 4 (5) 1 (3)
CYP2C9 Genotype 0.425
*1/*1 53 (70) 19 (66)
*1/*2 14 (18) 7 (24)
*1/*3 6 (8) 2 (7)
*2/*2 0 (-) 1 (3)
*2/*3 2 (3) 0 (-)
*3/*3 1 (1) 0 (-)
CYP2C19 Genotype 0.260
*1/*1 54 (71) 19 (66)
*1/*2 22 (29) 9 (31)
*2/*2 0 (-) 1 (3)
Responders Nonresponders P
N=76 (%)a N=29 (%)a
ABCB1 genotype (C3435T) 0.266
C/C 24 (32) 14 (48)
C/T 39 (51) 12 (41)
T/T 13 (17) 3 (10)
aDiscrepancies in total numbers correspond to genotyping missing data.
bPatients with 3 functional alleles of CYP2D6.
cNon available data on SNP/genotype in two subjects (1 Responder and 1
Nonresponder) due to methodological problems.
doi:10.1371/journal.pone.0019527.t002
Table 2. Cont.
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differences in methadone dose requirements and plasma concen-
trations depending on the phenotype status in CYP2D6, taking
patients all together: The 5 UM received higher doses of
methadone compared to EM (Tukey post-hoc analysis) (UM
177 mg/day [SD = 96] vs. EM 95 mg/day [SD = 60],
p = 0.043). PM required marginal lower doses of methadone
compared to other phenotypes (87 mg/day [SD = 67]). Plasmatic
concentrations showed similar results, with UM metabolizers
showing higher concentrations of (R)-, (S)- and (R,S)-methadone
(UM 1275 ng/ml [SD = 484] vs. EM 503 ng/ml [SD = 416],
p = 0.002; UM 707 ng/ml [SD = 267] vs. EM 263 ng/ml
[SD = 207], p,0.001; and UM 568 ng/ml [SD = 262] vs. EM
239 ng/ml [SD = 256], p = 0.048, respectively). A similar trend of
results was observed when grouping patients as a function of
clinical outcome (see Table 4).
Although results did not reach statistical significance, subjects
homozygous carriers of the CYP2B6*6 (associated with a
decreased activity of the enzyme) received lower doses of
methadone (74 mg/day [SD = 24] vs. 100 mg/day [SD = 65])
and displayed higher concentrations of (S)-methadone plasma
concentrations (347 ng/ml [SD = 279] vs. 265 ng/ml [SD = 269])
when compared with the rest of patients. (Supplementary
materials,Table S1).
Discussion
A number of genetic polymorphisms related to methadone
metabolic disposition and transport have been examined in terms
of their contribution to the clinical outcome (responders vs.
nonresponders) of patients in MMT. Their contribution to clinical
management and patient’s satisfaction is marginal. Nevertheless,
differences in methadone dosage have been found between
responder and nonresponder patients. These differences cannot
be attributed to genetic factors related to the pharmacokinetics of
methadone but to patients’ attitude in terms of accepting higher
doses of methadone. Some patients (nonresponders) refuse higher
doses of methadone.
Methadone patients categorized as responders and nonrespond-
ers on the basis of drug misuse while enrolled in the MMT differ
on the daily dose of methadone they receive (109668 mg/day vs.
72643 mg/day). These differences cannot be explained by
restrictions for upper limit in methadone dosage in the framework
of the MMT. A potential explanation of such dosage differences
and clinical outcome may come from alterations in methadone
pharmacokinetics due to genetic polymorphisms regulating it.
In the context of our study, the genetic polymorphisms of
CYP3A5, CYP2B6, CYP2C9, CYP2C19, and ABCB1 examined did
not influence methadone dosage. A small influence of CYP2D6
genetic polymorphism in methadone doses and plasma concen-
trations was found. Mean plasma concentrations of (R,S)-
methadone and of each enantiomer are not significantly different
between responders and nonresponders, although concentrations
in nonresponders were 30% lower than in responders in
agreement with differences in dose requirements between both
groups. Therefore, differences in clinical outcome cannot be
justified on the basis of some kind of genetic differences in
polymorphic drug metabolizing enzymes.
Concerning CYP2D6 genetic polymorphism, its contribution on
methadone metabolic disposition and dosage is controversial.
Several reports suggest that its contribution is negligible [17,58],
while others have shown that specific inhibitors of CYP2D6 as
paroxetine, markedly influence methadone disposition [29,30].
Five CYP2D6 UM subjects were identified among responder
patients while none among nonresponders. The UM phenotype
has been associated to lack of satisfaction of methadone treatment
[6] and with lower trough (R,S)-methadone plasma levels
compared to other CYP2D6 phenotypes [14], suggesting an
increased methadone metabolic disposition. In this study, UM
patients required high doses of methadone (about 180 mg), about
twice to those provided to EM patients. Nevertheless this increased
request of methadone is not related with an increased metabolic
disposition, as plasma concentrations of methadone and its
enantiomers are the highest among all CYP2D6 phenotypes. The
five PM patients included in this study (3 in the nonresponders and
2 in the responders groups) required marginally lower methadone
doses and display twice methadone plasma concentrations of EM
subjects, being methadone dosage quite similar. Observations
made in UM and PM patients are contradictory in terms of
methadone plasma concentrations (but not in terms of dosage) and
tune down the relevance of CYP2D6 in methadone metabolism.
Discrepancies between CYP2D6 genotype and phenotype in terms
of methadone metabolism have been already described [34]. The
observed discrepancies could be related to interactions with other
drugs as CYP2D6 has been implicated in the metabolism of other
Table 3. Phenotype frequencies of CYP3A5, CYP2D6, CYP2B6,
CYP2C9, CYP2C19 and ABCB1 between responder and
nonresponder groups.
Responders Nonresponders Pb
N=76 (%)a N=29 (%)a
CYP3A5 Phenotype 1.000
Extensive (*1/*1 1/*3) 12 (16) 3 (10)
Poor (*3/*3) 64 (84) 26 (90)
CYP2D6 Phenotype 0.032
Extensive (*1,*2, *3, *6, *35) 64 (84) 26 (90)
Ultrarapid (*1xN, *2xN) 5 (7) 0 (0)
Intermediate (*9*10,*41) 5 (7) 0 (0)
Poor (*4/*4) 2 (3) 3 (10)
CYP2B6 Phenotype 0,639
Extensive (*1/*1) 43 (57) 18 (62)
Poor (*6) 27 (36) 10 (35)
Ultrarapid (*4) 4 (5) 0 (-)
CYP2C9 Phenotype 0.779
Extensive (*1/*1, *1/*2) 67 (88) 26 (90)
Intermediate (*1/*3) 6 (8) 2 (7)
Poor (*2, *3) 3 (4) 1 (3)
CYP2C19 Phenotype 0.260
Extensive (*1/*1) 54 (71) 19 (66)
Intermediate (*1/*2) 22 (29) 9 (31)
Poor (*2/*2) 0 (-) 1 (3)
ABCB1 Phenotype (C3435T) 0.266
Extensive (C/C) 24 (32) 14 (48)
Intermediate (C/T) 39 (51) 12 (41)
Poor (T/T) 13 (17) 3 (10)
aDiscrepancies in total numbers correspond to genotyping missing data.
bBold numbers indicate statistically significant differences between patients.
cNon available data on SNP/genotype in two subjects (1 Responder and 1
Nonresponder) due to methodological problems. One patient showed *4/*6
genotype with unknown clinical significance, therefore it was not considered
in phenotype analysis.
doi:10.1371/journal.pone.0019527.t003
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medications [59]. The effect of drug interactions could not be
discarded in our results as a high proportion of patients were
taking concomitant medications (65%). Nevertheless present
observations should apply to EM patients, but not to PM patients
(homozygous for non-functional allelic variants) with a non-
functional enzyme or to UM (homozygous for more than two
functional allelic variants) the most susceptible to drug interactions
but also, those requiring the larger doses. A recent report suggests
that CYP2D6, a non-inducible hepatic enzyme, may be induced at
the brain level by nicotine [60]. As almost all participants were
smokers, there may be dissociation between plasma concentra-
tions, hepatic metabolism and genotype, and brain drug
requirements. According to previous publications [61] there is a
pharmacodynamic interaction between methadone treatment and
cigarette smoking; methadone and nicotine (smoking) share some
effects: increase the ratings of euphoria and ameliorate negative
mood. The contribution of CYP2D6 to methadone metabolism as
well the interaction with smoking deserves further studies.
Regarding the results of CYP2B6, although non-statistically
significant, methadone doses and methadone plasma concentrations
are in agreement with previous research reports: patients homozy-
gous for the *6 allele, received lower doses of methadone and those
patients showed higher plasma concentrations of (S)-methadone,
confirming previous findings [14]. Increased (S)-methadone plasma
concentrations are related with an enantioselective methadone
metabolic disposition towards the inactive (S)-enantiomer regulated
by CYP2B6*6 [19]. Also, in a recent report examining methadone
concentrations in post-mortem blood in methadone-related deaths,
it was concluded that the risk of methadone fatality may be related
in part with the CYP2B6*6 allele [62]. When we look at responder
status, 4 out of 5 slow metabolizers were classified as responders to
methadone treatment.
It is apparent from the present study that interindividual
pharmacokinetic differences among patients can be compensated
by clinical management of the doses of methadone (e.g. dose
requirements of UM patients). Although the absence of restrictions
in methadone dosage in our MMT program, the clinical
impression is that some patients with poor response to MMT do
not accept increases in their methadone dose [9]. It could be
hypothesized that those patients show significant adverse events
associated to methadone. (S)-methadone has been previously
associated to adverse responses of (R,S)-methadone as negative
mood effects –tension, fatigue, confusion…-.[5,63] No significant
differences in the (S)-methadone plasma concentrations have been
detected, nor in the (R)/(S) ratio in this sample. Other possible
explanations could be a pharmacodynamic influence in the
reluctance of a considerable group of patients to increase
methadone dose. The candidate gene OPRM1 has previously
been related to opioid treatment response, mainly in analgesia and
alcohol dependence [47,64,65]. The more commonly studied SNP
(A118G), in the mu-opioid receptor gene can affect opioid
function. Carriers of the homozygous variant (GG) require higher
opiate doses to achieve pain relief when they are treated with
morphine [66]. However, when genetic variability of this receptor
has been considered in MMT results have been negative [67] as in
our study. These negative findings may suggest that these variants
are specifically involved in the heroin dependence phenotype but
not in the individual differences in the response to methadone
treatment in heroin addiction.
An influence of a on the DRD2 gene promoter (rs1800497
C.T) has been associated with both, the risk of opiate addiction,
leading to the necessity of methadone substitution therapy, and the
course of this therapy in terms of dosage requirements [68]. Other
pharmacodynamic influences in those patients could be a
difference related to the activation of kappa opioid receptors.
Kappa opioid receptors have been involved in the response to
drugs (cocaine, alcohol and opiates) [69] in opiate withdrawal and
stress responsivity [70]; kappa agonists lower the levels of
dopamine in the nucleus accumbens and act in a counter-
modulatory manner to attenuate the increase in dopamine levels
[71] and induce a negative mood state [70].
The negative results in terms of the contribution of genotypes and
phenotypes of drug metabolizing enzymes examined in this study on
the clinical outcomes of MMT are consistent with previous data
[14,37,72]. Classically, treatment response has been evaluated in
terms of retention in treatment and opioid consumption measured
by urine drug tests. In recent years, aspects as patients’ satisfaction
with the MMT program are considered important in the outcome
[73,74] also, personal attitudes as coping self-efficacy have recently
received attention [4].
Among other factors to take into consideration in response to
methadone maintenance treatment is the duration of treatment.
As seen in our results, responder patients stayed in treatment more
than twice than nonresponders (52 vs 21 months). Some studies
have shown that the results obtained after treatment over a period
of less than 3 months were comparable to those obtained after no
treatment at all [75] and others described reduction in drug use
when patients remained in treatment for at least one year [76].
The present findings should be interpreted taking into account
some limitations of the study. Firstly, the sample size was small;
complex study procedures in the framework of a longitudinal
design (urine testing, blood analyses for genotyping, time
consuming interviews) can result in a non-negligible number of
patients with incomplete follow-up data. It is also remarkable that
patients with poorer outcomes (for example, more illicit drug use)
were more reluctant to accept to participate in clinical studies; this
could imply a bias in the study results, but, on the other hand, to
offer a payment for the participation it is not acceptable on ethical
grounds. Lastly, we cannot exclude a risk of stratification effect,
although all subjects were Caucasian.
Globally from the present study, it is apparent that interindi-
vidual pharmacokinetic differences among patients can be
compensated by clinical management of the doses of methadone,
with little influence, if any, from pharmacogenetics of drug
metabolizing enzymes and protein transporters. The interest
should to be driven towards the genetics of pharmacodynamics in
methadone treatment response.
Supporting Information
Table S1 Mean methadone dose requirements of patients
(n = 105) and (R)-, (S)- and (R,S)-methadone plasma concentra-
tions (n = 79) according phenotypes of genes evaluated (CYP3A5,
CYP2D6, CYP2B6, CYP2C9, CYP2C19 and ABCB1).
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